{"title":"初次治疗和药物无效精神分裂症患者自闭症特征的发生率和临床相关性。","authors":"Hong Zhang, Lin Zhang, Zhihua Liu, Jun Ma","doi":"10.5152/alphapsychiatry.2024.241626","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>A distinct subtype of schizophrenia (SCZ) is the one accompanied with autistic features (AF). This study aimed to determine the prevalence of AF in initial-treatment and drug-naive (ITDN) patients with SCZ and investigate its influencing factors.</p><p><strong>Methods: </strong>The study recruited 710 ITDN patients with SCZ. Their sociodemographic data and general clinical information were collected, and a clinical psychological assessment was performed to quantify their psychopathology and disease severity. The severity of AF was calculated based on psychopathology scores.</p><p><strong>Results: </strong>Overall, 19.01% (135/710) patients with SCZ showed AF. Patients with AF exhibited higher levels of thyroid-stimulating hormone (TSH) (<i>t</i> = -4.54, <i>P</i> < .001) and lower levels of free triiodothyronine (FT<sub>3</sub>) and free tetraiodothyronine (FT<sub>4</sub>) (<i>t</i> = 2.38, <i>P</i> = .018; <i>t</i> = 3.19, <i>P</i> = .002) than those with AF. Binary logistic regression analysis revealed waist circumference (<i>B</i> = 0.03, <i>P</i> = .022, odds ratio (OR) = 1.03) and TSH level (<i>B</i> = 0.54, <i>P</i> < .001, OR = 1.71) as risk factors for AF, and deemed low-density lipoprotein cholesterol (<i>B</i> = -0.43, <i>P</i> = .025, OR = 0.65), fasting blood glucose (<i>B</i> = -0.72, <i>P</i> = .013, OR = 0.49), FT<sub>3</sub> (<i>B</i> = -0.32, <i>P</i> = .034, OR = 0.73), and FT<sub>4</sub> (<i>B</i> = -0.08, <i>P</i> = .025, OR = 0.93) levels as protective factors. Multiple linear regression analysis identified FT<sub>3</sub> level (<i>B</i> = -0.85, <i>t</i> = -2.22, <i>P</i> = .028, 95%, Confidence Intervals (CI): -1.61- -0.09) as a protective factor influencing AF severity.</p><p><strong>Conclusion: </strong>This study reports the prevalence of AF in the target SCZ population and identifies factors associated with its development and severity. The discernment of these distinctive clinical features may facilitate formulation of tailored prevention strategies and interventions for this precise subset of SCZ patients.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"25 5","pages":"611-616"},"PeriodicalIF":1.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562552/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence and Clinical Correlates of Autistic Features in Patients with Initial-Treatment and Drug-Naive Schizophrenia.\",\"authors\":\"Hong Zhang, Lin Zhang, Zhihua Liu, Jun Ma\",\"doi\":\"10.5152/alphapsychiatry.2024.241626\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>A distinct subtype of schizophrenia (SCZ) is the one accompanied with autistic features (AF). This study aimed to determine the prevalence of AF in initial-treatment and drug-naive (ITDN) patients with SCZ and investigate its influencing factors.</p><p><strong>Methods: </strong>The study recruited 710 ITDN patients with SCZ. Their sociodemographic data and general clinical information were collected, and a clinical psychological assessment was performed to quantify their psychopathology and disease severity. The severity of AF was calculated based on psychopathology scores.</p><p><strong>Results: </strong>Overall, 19.01% (135/710) patients with SCZ showed AF. Patients with AF exhibited higher levels of thyroid-stimulating hormone (TSH) (<i>t</i> = -4.54, <i>P</i> < .001) and lower levels of free triiodothyronine (FT<sub>3</sub>) and free tetraiodothyronine (FT<sub>4</sub>) (<i>t</i> = 2.38, <i>P</i> = .018; <i>t</i> = 3.19, <i>P</i> = .002) than those with AF. Binary logistic regression analysis revealed waist circumference (<i>B</i> = 0.03, <i>P</i> = .022, odds ratio (OR) = 1.03) and TSH level (<i>B</i> = 0.54, <i>P</i> < .001, OR = 1.71) as risk factors for AF, and deemed low-density lipoprotein cholesterol (<i>B</i> = -0.43, <i>P</i> = .025, OR = 0.65), fasting blood glucose (<i>B</i> = -0.72, <i>P</i> = .013, OR = 0.49), FT<sub>3</sub> (<i>B</i> = -0.32, <i>P</i> = .034, OR = 0.73), and FT<sub>4</sub> (<i>B</i> = -0.08, <i>P</i> = .025, OR = 0.93) levels as protective factors. Multiple linear regression analysis identified FT<sub>3</sub> level (<i>B</i> = -0.85, <i>t</i> = -2.22, <i>P</i> = .028, 95%, Confidence Intervals (CI): -1.61- -0.09) as a protective factor influencing AF severity.</p><p><strong>Conclusion: </strong>This study reports the prevalence of AF in the target SCZ population and identifies factors associated with its development and severity. The discernment of these distinctive clinical features may facilitate formulation of tailored prevention strategies and interventions for this precise subset of SCZ patients.</p>\",\"PeriodicalId\":72151,\"journal\":{\"name\":\"Alpha psychiatry\",\"volume\":\"25 5\",\"pages\":\"611-616\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562552/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alpha psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5152/alphapsychiatry.2024.241626\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alpha psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/alphapsychiatry.2024.241626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Prevalence and Clinical Correlates of Autistic Features in Patients with Initial-Treatment and Drug-Naive Schizophrenia.
Objective: A distinct subtype of schizophrenia (SCZ) is the one accompanied with autistic features (AF). This study aimed to determine the prevalence of AF in initial-treatment and drug-naive (ITDN) patients with SCZ and investigate its influencing factors.
Methods: The study recruited 710 ITDN patients with SCZ. Their sociodemographic data and general clinical information were collected, and a clinical psychological assessment was performed to quantify their psychopathology and disease severity. The severity of AF was calculated based on psychopathology scores.
Results: Overall, 19.01% (135/710) patients with SCZ showed AF. Patients with AF exhibited higher levels of thyroid-stimulating hormone (TSH) (t = -4.54, P < .001) and lower levels of free triiodothyronine (FT3) and free tetraiodothyronine (FT4) (t = 2.38, P = .018; t = 3.19, P = .002) than those with AF. Binary logistic regression analysis revealed waist circumference (B = 0.03, P = .022, odds ratio (OR) = 1.03) and TSH level (B = 0.54, P < .001, OR = 1.71) as risk factors for AF, and deemed low-density lipoprotein cholesterol (B = -0.43, P = .025, OR = 0.65), fasting blood glucose (B = -0.72, P = .013, OR = 0.49), FT3 (B = -0.32, P = .034, OR = 0.73), and FT4 (B = -0.08, P = .025, OR = 0.93) levels as protective factors. Multiple linear regression analysis identified FT3 level (B = -0.85, t = -2.22, P = .028, 95%, Confidence Intervals (CI): -1.61- -0.09) as a protective factor influencing AF severity.
Conclusion: This study reports the prevalence of AF in the target SCZ population and identifies factors associated with its development and severity. The discernment of these distinctive clinical features may facilitate formulation of tailored prevention strategies and interventions for this precise subset of SCZ patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
